Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 488,363
  • Shares Outstanding, K 87,835
  • Annual Sales, $ 30,910 K
  • Annual Income, $ -209,470 K
  • EBIT $ -170 M
  • EBITDA $ -169 M
  • 60-Month Beta 0.40
  • Price/Sales 16.11
  • Price/Cash Flow N/A
  • Price/Book 7.71

Options Overview Details

View History
  • Implied Volatility 273.95% (-43.76%)
  • Historical Volatility 59.03%
  • IV Percentile 79%
  • IV Rank 29.08%
  • IV High 755.94% on 03/03/26
  • IV Low 76.27% on 03/28/25
  • Expected Move (DTE 1) 0.47 (8.03%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 728
  • Volume Avg (30-Day) 509
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 13,818
  • Open Int (30-Day) 11,150
  • Expected Range 5.35 to 6.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.46
  • Number of Estimates 1
  • High Estimate -0.46
  • Low Estimate -0.46
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +52.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.31 +9.60%
on 03/19/26
6.79 -14.29%
on 03/09/26
-0.12 (-2.02%)
since 02/19/26
3-Month
5.31 +9.60%
on 03/19/26
8.88 -34.46%
on 01/07/26
-1.94 (-25.00%)
since 12/19/25
52-Week
4.01 +45.14%
on 06/30/25
11.24 -48.24%
on 09/05/25
-1.16 (-16.62%)
since 03/19/25

Most Recent Stories

More News
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical...

VSTM : 5.82 (+4.68%)
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers

Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial

VSTM : 5.82 (+4.68%)
Verastem: Q4 Earnings Snapshot

Verastem: Q4 Earnings Snapshot

VSTM : 5.82 (+4.68%)
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 ...

VSTM : 5.82 (+4.68%)
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 5.82 (+4.68%)
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million...

VSTM : 5.82 (+4.68%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase...

VSTM : 5.82 (+4.68%)
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim...

VSTM : 5.82 (+4.68%)
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development ...

VSTM : 5.82 (+4.68%)
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 5.82 (+4.68%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 6.75
2nd Resistance Point 6.36
1st Resistance Point 6.09
Last Price 5.82
1st Support Level 5.43
2nd Support Level 5.04
3rd Support Level 4.77

See More

52-Week High 11.24
Fibonacci 61.8% 8.48
Fibonacci 50% 7.63
Fibonacci 38.2% 6.77
Last Price 5.82
52-Week Low 4.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar